These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24700157)

  • 21. Update on the management of chronic kidney disease.
    Rivera JA; O'Hare AM; Harper GM
    Am Fam Physician; 2012 Oct; 86(8):749-54. PubMed ID: 23062158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression of renal failure and lipids--is there evidence for a link in humans?
    Attman PO
    Nephrol Dial Transplant; 1998 Mar; 13(3):545-7. PubMed ID: 9550623
    [No Abstract]   [Full Text] [Related]  

  • 23. Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
    Falkevall A; Mehlem A; Palombo I; Heller Sahlgren B; Ebarasi L; He L; Ytterberg AJ; Olauson H; Axelsson J; Sundelin B; Patrakka J; Scotney P; Nash A; Eriksson U
    Cell Metab; 2017 Mar; 25(3):713-726. PubMed ID: 28190774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic kidney disease in diabetes.
    ; McFarlane P; Gilbert RE; MacCallum L; Senior P
    Can J Diabetes; 2013 Apr; 37 Suppl 1():S129-36. PubMed ID: 24070935
    [No Abstract]   [Full Text] [Related]  

  • 25. Beyond the traditional lipid parameters in chronic kidney disease.
    Bermúdez-López M; Betriu À; Valdivielso JM; Bretones Del Pino T; Arroyo D; Fernández E
    Nefrologia (Engl Ed); 2018; 38(2):109-113. PubMed ID: 29137894
    [No Abstract]   [Full Text] [Related]  

  • 26. [Aldosterone exacerbates chronic renal insufficiency].
    Kristensen KE; Egfjord M
    Ugeskr Laeger; 2011 Jan; 173(4):267-70. PubMed ID: 21262170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnosis and management of diabetic nephropathy].
    Kitada M; Koya D
    Nihon Rinsho; 2015 Dec; 73(12):2037-43. PubMed ID: 26666150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic kidney disease in 2012].
    Imai E
    Nihon Jinzo Gakkai Shi; 2013; 55(1):48-55. PubMed ID: 23461210
    [No Abstract]   [Full Text] [Related]  

  • 29. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease.
    Gugliucci A; Menini T
    Adv Exp Med Biol; 2014; 824():191-208. PubMed ID: 25039001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Acid-Base Homeostasis in Diabetic Kidney Disease.
    Khairallah P; Scialla JJ
    Curr Diab Rep; 2017 Apr; 17(4):28. PubMed ID: 28343312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bariatric surgery and kidney disease outcomes in severely obese youth.
    Bjornstad P; Nehus E; van Raalte D
    Semin Pediatr Surg; 2020 Feb; 29(1):150883. PubMed ID: 32238288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions.
    Sudhakaran S; Bottiglieri T; Tecson KM; Kluger AY; McCullough PA
    Rev Cardiovasc Med; 2018 Sep; 19(3):77-88. PubMed ID: 31054556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid lowering in liver and chronic kidney disease.
    Herrick C; Litvin M; Goldberg AC
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlations between plasma strontium concentration, components of calcium and phosphate metabolism and renal function in type 2 diabetes mellitus.
    van den Berkhof YS; Gant CM; Maatman R; De Graaf A; Navis GJ; Bakker SJL; Laverman GD
    Eur J Clin Invest; 2018 Sep; 48(9):e12987. PubMed ID: 29931675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell adhesion molecule-1 shedding induces apoptosis of renal epithelial cells and exacerbates human nephropathies.
    Kato T; Hagiyama M; Takashima Y; Yoneshige A; Ito A
    Am J Physiol Renal Physiol; 2018 Mar; 314(3):F388-F398. PubMed ID: 29070574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopressin and diabetic nephropathy.
    Roussel R; Velho G; Bankir L
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):311-318. PubMed ID: 28403013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
    Fioretto P; Stefansson BV; Johnsson E; Cain VA; Sjöström CD
    Diabetologia; 2016 Sep; 59(9):2036-9. PubMed ID: 27306615
    [No Abstract]   [Full Text] [Related]  

  • 38. Renoprotective effect of myricetin restrains dyslipidemia and renal mesangial cell proliferation by the suppression of sterol regulatory element binding proteins in an experimental model of diabetic nephropathy.
    Kandasamy N; Ashokkumar N
    Eur J Pharmacol; 2014 Nov; 743():53-62. PubMed ID: 25240712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased indoleamine 2,3-dioxygenase activity in type 2 diabetic nephropathy.
    Zhang Y; Ruan Y; Zhang P; Wang L
    J Diabetes Complications; 2017 Jan; 31(1):223-227. PubMed ID: 27646613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 4. Dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Naika Gakkai Zasshi; 2012 May; 101(5):1294-302. PubMed ID: 22693849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.